Does RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E Cause Off label use? 22 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 22 reports of Off label use have been filed in association with RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E. This represents 4.8% of all adverse event reports for RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E.
22
Reports of Off label use with RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E
4.8%
of all RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E reports
0
Deaths
9
Hospitalizations
How Dangerous Is Off label use From RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E?
Of the 22 reports, 9 (40.9%) required hospitalization.
Is Off label use Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E. However, 22 reports have been filed with the FAERS database.
What Other Side Effects Does RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E Cause?
Herpes zoster (112)
Pain (93)
Vaccination failure (74)
Rash (64)
Pyrexia (50)
Fatigue (48)
Drug ineffective (44)
Nausea (40)
Pain in extremity (38)
Arthralgia (36)
What Other Drugs Cause Off label use?
RITUXIMAB (39,751)
INFLIXIMAB (34,801)
DENOSUMAB (34,612)
METHOTREXATE (24,020)
VEDOLIZUMAB (21,017)
ETANERCEPT (20,178)
TOCILIZUMAB (18,256)
PREDNISONE (17,867)
LENALIDOMIDE (17,017)
ADALIMUMAB (16,417)
Which RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E Alternatives Have Lower Off label use Risk?
RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E vs REGADENOSON
RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E vs REGORAFENIB
RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E vs REGORAFENIB\REGORAFENIB
RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E vs RELATLIMAB
RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E vs RELPAX